Key result
Aminoguanidine therapy (50 mg/kg daily) prevented contractile dysfunction and the augmentation in left ventricular internal resistance in rats with induced type 2 diabetes.
Why the study?
Does aminoguanidine improve cardiac pumping mechanics in rats with STZ and NA-induced type 2 diabetes?
Population
Rats with streptozotocin (STZ) and nicotinamide (NA)-induced type 2 diabetes
Comparison
Aminoguanidine 50 mg kg, i.p. daily for 8 weeks vs Age-matched, untreated, diabetic controls
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Should not change clinical practice; leaves open translation of aminoguanidine effects on ventricular mechanics to human diabetes.
Does aminoguanidine improve cardiac pumping mechanics in rats with STZ and NA-induced type 2 diabetes?
Aminoguanidine therapy prevents contractile dysfunction and augmentation in LV internal resistance in a rat model of type 2 diabetes.
Wu et al. (2008) studied Type 2 diabetes (streptozotocin and nicotinamide-induced). Aminoguanidine vs. Age-matched, untreated, diabetic controls was evaluated on Maximal systolic elastance (E(max)) and theoretical maximum flow (Q(max)). Aminoguanidine therapy (50 mg/kg daily) prevented contractile dysfunction and the augmentation in left ventricular internal resistance in rats with induced type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: